Trial Profile
A phase I, open-label, multi-dose, dose-escalation study of GW572016 [lapatinib] in patients with solid tumorL
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 29 May 2007
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 May 2007 New trial record.